Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

potentially bringing it into competition with biotech heavyweights such as Alnylam, something that Mortazavi focused on during his long time at the helm of Silence Therapeutics. The company has ...

The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat conditions like Huntington’s.

The plot thickens in the messy legal battle between Blake Lively and Justin Baldoni, which began after the release of their film It Ends With Us. While both sides have accused the other of bad ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known ...

Is Alnylam Pharmaceuticals (ALNY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1010 individual ...

He writes about those retreats, and the lessons they’ve imparted, in his new book, “Aflame: Learning From Silence.” Iyer joins us on the podcast this week to talk about his new memoir and ...